Abstract Background The objective of this study was to evaluate if mammography screening attendance is associated with a reduction in late-stage breast cancer incidence. Methods The cohort included ...over 400,000 Italian women who were first invited to participate in regional screening programmes during the 1990s and were followed for breast cancer incidence for 13 years. We obtained individual data on their exposure to screening and correlated this with total and stage-specific breast cancer incidence. Socio-economic status and pre-screening incidence data were used to assess the presence of self-selection bias. Results Overall, screening attendance was associated with a 10% excess risk of in situ and invasive breast cancer (IRR = 1.10; 95% confidence interval (CI): 1.06–1.14), which dropped to 5% for invasive cancers only (IRR = 1.05; 95% CI: 1.01–1.09). There were significant reductions among attenders for specific cancer stages; we observed a 39% reduction for T2 or larger (IRR = 0.61; 95% CI: 0.57–0.66), 19% for node positives (IRR = 0.81; 95% CI: 0.76–0.86) and 28% for stage II and higher (IRR = 0.72; 95% CI: 0.68–0.76). Our data suggest that the presence of self-selection bias is limited and, overall, invited women experienced a 17% reduction of advanced cancers compared with pre-screening rates. Conclusions Comparing attenders' and non-attenders' stage-specific breast cancer incidence, we have estimated that screening attendance is associated with a reduction of nearly 30% for stages II+.
Context.Metal-rich globular clusters trace the formation of bulges. Abundance ratios in the metal-rich globular clusters such as NGC 6553 can constrain the formation timescale of the Galactic bulge. ...Aims.The purpose of this study is to determine the metallicity and elemental ratios in individual stars of the metal-rich bulge globular cluster NGC 6553. Methods.A detailed abundance analysis of four giants in NGC 6553 is carried out, based on optical high-resolution échelle spectra obtained with UVES at the ESO VLT-UT2 Kueyen telescope. Results.A metallicity Fe/H = -0.20 dex is derived, together with α-element enhancement of Mg and Si (Mg/Fe = +0.28, Si/Fe = +0.21), solar Ca and Ti (Ca/Fe = +0.05, Ti/Fe = -0.01), and a mild enhancement of the r-process element Eu with Eu/Fe = +0.10. A mean heliocentric radial velocity of -1.86 km s-1 is measured. We compare our results with previous investigations of the cluster.
We report the discovery of a substellar companion to the intermediate-mass star HD 11977 (G5 III). Radial velocities of this star have been monitored for five years with FEROS at the 1.52-m ESO and ...later at the 2.2-m MPG/ESO telescope in La Silla, Chile. Based on the collected data we calculated an orbital solution with a period of $P=711~{\rm days}$, a semi-amplitude of $K_{1}=105~{\rm m\,s}^{-1}$, and an eccentricity of $e=0.4$. The period of the radial-velocity variation is longer than that of the estimated stellar rotation, rendering it unlikely that rotational modulation is the source of the variation in the radial velocity. This hypothesis is supported by the absence of a correlation between stellar activity indicators and radial-velocity variation. By determining a primary stellar mass of $M_{\star}=1.91~M_{\odot}$, the best-fit minimum mass of the companion and semi-major axis of the orbit are $m_{2}\sin{i}=6.54~M_{{\rm Jup}}$ and $a_{2}=1.93~{\rm AU}$, respectively. An upper limit for the mass of the companion of $m_{2} \la 65.5~M_{{\rm Jup}}$ has been calculated from Hipparcos astrometric measurements. Although the possibility of a brown-dwarf companion cannot be excluded, HD 11977 B is one of the few planet candidates detected around an intermediate-mass star. The progenitor main-sequence star of HD 11977 is probably an A-type star. This discovery gives an indirect evidence for planetary companions around early type main-sequence stars.
PDRs4All Trahin, Boris; Habart, Emilie; Alarcón, Felipe ...
Astronomy and astrophysics (Berlin),
07/2024, Letnik:
687
Journal Article
Recenzirano
Context. Mid-infrared emission features are important probes of the properties of ionized gas and hot or warm molecular gas, which are difficult to probe at other wavelengths. The Orion Bar ...photodissociation region (PDR) is a bright, nearby, and frequently studied target containing large amounts of gas under these conditions. Under the “PDRs4All” Early Release Science Program for JWST, a part of the Orion Bar was observed with MIRI integral field unit (IFU) spectroscopy, and these high-sensitivity IR spectroscopic images of very high angular resolution (0.2″) provide a rich observational inventory of the mid-infrared (MIR) emission lines, while resolving the H II region, the ionization front, and multiple dissociation fronts. Aims. We list, identify, and measure the most prominent gas emission lines in the Orion Bar using the new MIRI IFU data. An initial analysis summarizes the physical conditions of the gas and demonstrates the potential of these new data and future IFU observations with JWST. Methods. The MIRI IFU mosaic spatially resolves the substructure of the PDR, its footprint cutting perpendicularly across the ionization front and three dissociation fronts. We performed an up-to-date data reduction, and extracted five spectra that represent the ionized, atomic, and molecular gas layers. We identified the observed lines through a comparison with theoretical line lists derived from atomic data and simulated PDR models. The identified species and transitions are summarized in the main table of this work, with measurements of the line intensities and central wavelengths. Results. We identified around 100 lines and report an additional 18 lines that remain unidentified. The majority consists of H I recombination lines arising from the ionized gas layer bordering the PDR. The H I line ratios are well matched by emissivity coefficients from H recombination theory, but deviate by up to 10% because of contamination by He I lines. We report the observed emission lines of various ionization stages of Ne, P, S, Cl, Ar, Fe, and Ni. We show how the Ne III/Ne II, S IV/S III, and Ar III/Ar II ratios trace the conditions in the ionized layer bordering the PDR, while Fe III/Fe II and Ni III/Ni II exhibit a different behavior, as there are significant contributions to Fe II and Ni II from the neutral PDR gas. We observe the pure-rotational H2 lines in the vibrational ground state from 0–0 S(1) to 0–0 S (8), and in the first vibrationally excited state from 1–1 S (5) to 1–1 S(9). We derive H2 excitation diagrams, and for the three observed dissociation fronts, the rotational excitation can be approximated with one thermal (~700 K) component representative of an average gas temperature, and one nonthermal component (~2700 K) probing the effect of UV pumping. We compare these results to an existing model of the Orion Bar PDR, and find that the predicted excitation matches the data qualitatively, while adjustments to the parameters of the PDR model are required to reproduce the intensity of the 0–0 S (6) to S (8) lines.
PDRs4All Van De Putte, Dries; Trahin, Boris; Habart, Emilie ...
Astronomy and astrophysics (Berlin),
7/2024, Letnik:
687
Journal Article
Recenzirano
Context. Mid-infrared emission features are important probes of the properties of ionized gas and hot or warm molecular gas, which are difficult to probe at other wavelengths. The Orion Bar ...photodissociation region (PDR) is a bright, nearby, and frequently studied target containing large amounts of gas under these conditions. Under the “PDRs4All” Early Release Science Program for JWST, a part of the Orion Bar was observed with MIRI integral field unit (IFU) spectroscopy, and these high-sensitivity IR spectroscopic images of very high angular resolution (0.2″) provide a rich observational inventory of the mid-infrared (MIR) emission lines, while resolving the H II region, the ionization front, and multiple dissociation fronts. Aims. We list, identify, and measure the most prominent gas emission lines in the Orion Bar using the new MIRI IFU data. An initial analysis summarizes the physical conditions of the gas and demonstrates the potential of these new data and future IFU observations with JWST. Methods. The MIRI IFU mosaic spatially resolves the substructure of the PDR, its footprint cutting perpendicularly across the ionization front and three dissociation fronts. We performed an up-to-date data reduction, and extracted five spectra that represent the ionized, atomic, and molecular gas layers. We identified the observed lines through a comparison with theoretical line lists derived from atomic data and simulated PDR models. The identified species and transitions are summarized in the main table of this work, with measurements of the line intensities and central wavelengths. Results. We identified around 100 lines and report an additional 18 lines that remain unidentified. The majority consists of H I recombination lines arising from the ionized gas layer bordering the PDR. The H I line ratios are well matched by emissivity coefficients from H recombination theory, but deviate by up to 10% because of contamination by He I lines. We report the observed emission lines of various ionization stages of Ne, P, S, Cl, Ar, Fe, and Ni. We show how the Ne III /Ne II , S IV /S III , and Ar III /Ar II ratios trace the conditions in the ionized layer bordering the PDR, while Fe III /Fe II and Ni III /Ni II exhibit a different behavior, as there are significant contributions to Fe II and Ni II from the neutral PDR gas. We observe the pure-rotational H 2 lines in the vibrational ground state from 0–0 S (1) to 0–0 S (8), and in the first vibrationally excited state from 1–1 S (5) to 1–1 S(9). We derive H 2 excitation diagrams, and for the three observed dissociation fronts, the rotational excitation can be approximated with one thermal (~700 K) component representative of an average gas temperature, and one nonthermal component (~2700 K) probing the effect of UV pumping. We compare these results to an existing model of the Orion Bar PDR, and find that the predicted excitation matches the data qualitatively, while adjustments to the parameters of the PDR model are required to reproduce the intensity of the 0–0 S (6) to S (8) lines.
Introduction
Renal dysfunction is a recognized risk factor for mortality after HCT, as it is included in the comorbidity index (HCT CI). Yet, further understanding on outcomes in patients with ...different level of renal dysfunction or undergoing hemodialysis (HD) at time of transplant remains scant. This study explores the impact of different levels renal dysfunction on major HCT outcomes in a large population using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
Methods
The study population included 8,102 patients age 40 years and older who received HCT for treatment of malignancies from 2008 to 2016, with available pre-transplant creatinine measurement. eGFR, calculated using CKD-EPI (CKD-epidemiology collaboration) method, was used to assigned patients in four categories: eGFR ≥ 90ml/min (eGFR≥ 90, N=4,237, reference), eGFR 60-90ml/min (eGFR 60-90, N=3,158), eGFR 45-59ml/min (eGFR 45-59, N=538) and eGFR <45ml/min(eGFR<45, N=169). A separate cohort of patients on HD at time of HCT (N=46) was analyzed independently. Multivariate analysis models were built for assessment of overall mortality, transplant-related mortality (TRM), disease relapse or progression, graft-versus-host disease (GVHD), hepatic sinusoidal obstructive syndrome (SOS), thrombotic microangiopathy (TMA), idiopathic pneumonia syndrome (IPS) and need of HD post-transplant. Common patient-, disease- and transplant-related covariates were tested on all models and HCT CI was computed without reported renal dysfunction comorbidity to avoid collinearity.
Results
Patient characteristics are shown in table 1. The groups were comparable on disease risk index, graft and donor source, but patients with eGFR>90 were younger and received myeloablative conditioning more frequently. The cohort of eGFR <45 had a higher proportion of patients with HCT CI ≥3. TRM and overall survival according to eGFR groups are shown in Figure. In the multivariate analysis models eGFR as the main effect was associated with TRM (p<0.0001), overall mortality (p<0.0001), and requirement of HD post HCT (p<0.0001), but not for relapse/progression (p=0.98), GVHD (grades II-IV, p=0.34; III-IV, p=0.70; and chronic, p=0.20), TMA (p=0.46), SOS (p=0.02) or IPS (p=0.06). Compared to eGFR ≥90, the hazard ratio (HR) for TRM for eGFR 60-89 was 1.12 (p=0.07), for eGFR 45-59 was 1.46 (p<0.001) and for eGFR<45 was 1.74 (p=0.004). Corresponding HRs for overall mortality were 1.0 (p=0.9), 1.17 (p=0.03) and 1.63 (p<0.0001), respectively. Similarly, for the need of HD post HCT, HR for eGFR60-89 was 1.29 (p=0.03), eGFR45-59 was 2.45 (p<0.001) and for eGFR<45 was 3.09 (p<0.0001). Only eGFR<45 was associated with higher risk of SOS (HR2.66, p=0.03). Among 46 patients on HD prior to HCT, one-year probability of overall survival was 20% (95% Confidence Interval CI 10-32%) and cumulative incidence of TRM at one year was 67% (95% CI, 50-81%).
Conclusion
These findings indicate that degree of renal dysfunction is an independent predictor of OS, TRM, probability of receiving HD and SOS when adjusted for other risk factors. The impact of eGFR on the need of HD, a complication that increases morbidity post HCT is an important finding. Additionally, the outcomes of a subset of patients on HD at time of transplants are dismal. These results can further assist the prognostic assessment of candidates for an allogeneic HCT.
Display omitted
Stadtmauer:Celgene: Consultancy; Takeda: Consultancy; Janssen: Consultancy; Amgen: Consultancy; Novartis: Consultancy, Research Funding; Tmunity: Research Funding; Abbvie: Research Funding. Wingard:Ansun: Consultancy; Pluristem: Consultancy; Celgene: Consultancy; Merck: Consultancy; Shire: Consultancy. Ganguly:Seattle Genetics: Speakers Bureau; Daiichi Sankyo: Research Funding; Kite Pharma: Honoraria, Other: Advisory Board; Janssen: Honoraria, Other: Advisory Board. Pasquini:Pfizer: Other: Advisory Board; Amgen: Consultancy; Medigene: Consultancy; BMS: Research Funding; Novartis: Research Funding; Kit Pharma: Research Funding.
Context. We found evidence for a sub–stellar companion around the K giant star HD 110014. This cool evolved star, with a spectral type K2III and an estimated mass between 1.9 and 2.4 $M_{\odot}$, is ...slightly metal rich with Fe/H = 0.19 and a rotational velocity $V \sin i\ $ = 2.0 km s-1. Aims. To search for extrasolar planets around intermediate-mass stars and to improve our knowledge of the nature of radial velocity variations shown by G and K giant stars. Methods. Based on radial velocity analysis, we found evidence for a substellar companion with a planetary mass and long orbital period. The Radial velocity variation of HD 110014 has been monitored from 2000 until 2007 with FEROS at 1.5 m ESO and at the 2.2 m MPG/ESO, HARPS at the 3.6 m ESO and Coralie at 1.2 m Leonard Euler swiss telescopes in La Silla observatory. The radial velocities were computed by using a cross-correlation technique. Line bisector, Hipparcos photometry and chromospheric lines were analyzed to exclude other root-causes for the radial velocity variability. Results. We report the presence of an extrasolar planet around the giant star HD 110014, with an orbital period of $835.48 \pm 6.04$ days. A Keplerian orbit, with an eccentricity $e = 0.462\pm 0.069$, yields a minimum mass $M \sin i$ = 11.09 $M_{{\rm Jup}}$. The analysis of the residuals shows evidence for a second RV variability with a period of 130 days and an amplitude of ±100 ms-1 . Its nature is not completely clear, but a second planet is a possible explanation.
We studied thermal and dynamic history effects in the vortex lattice (VL) near the order-disorder transition in clean NbSe2 single crystals. Comparing the evolution of the effective vortex pinning ...and the bulk VL structure, we observed metastable superheated and supercooled VL configurations that coexist with a hysteretic effective pinning response due to thermal cycling of the system. A novel scenario, governed by the interplay between (lower) elastic and (higher) plastic energy barriers, is proposed as an explanation for our observations: Plastic barriers, which prevent the annihilation or creation of topological defects, require dynamic assistance to be overcome and to achieve a stable VL at each temperature. Conversely, thermal hysteresis in the pining response is ascribed to low energy barriers, which inhibit rearrangement within a single VL correlation volume and are easily overcome as the relative strength of competing interactions changes with temperature.
In the CALGB (Alliance) 100104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for patients with newly diagnosed myeloma. That study showed ...improved time to progression and overall survival and an increase in second primary malignancies for lenalidomide at a median follow-up of 34 months. Here we report an updated intention-to-treat analysis of CALGB (Alliance) 100104 at a median follow-up of 91 months.
Patients were eligible for this randomised, double-blind, placebo-controlled, phase 3 trial if they had symptomatic disease requiring treatment; had received, at most, two induction regimens; and had achieved stable disease or better in the first 100 days after ASCT. We randomly assigned patients to either lenalidomide or placebo groups using permuted block randomisation, with a fixed block size of six. Randomisation was stratified by three factors: normal or elevated β2 microglobulin concentration at registration (≤2·5 mg/L vs >2·5 mg/L), previous use or non-use of thalidomide during induction therapy, and previous use or non-use of lenalidomide during induction therapy. The starting dose was two capsules (10 mg) per day, escalated to three capsules (15 mg) per day after 3 months. The primary endpoint was time to progression (time of progressive disease or death from any cause), with intention-to-treat analysis. This study is registered with ClinicalTrials.gov, identifier NCT00114101. New patients are no longer being recruited, but some patients remain on treatment and in follow-up.
Between April 14, 2005, and July 2, 2009, 460 patients were randomly assigned to receive either lenalidomide (n=231) or placebo (n=229). After three interim analyses, the study was unblinded at a median follow-up of 18 months, at which point 86 (67%) of 128 patients without progressive disease in the placebo group chose to cross over to the lenalidomide group. The median follow-up for the updated survival analysis, as of Oct 19, 2016, was 91 months (IQR 83·6-103·1). The median time to progression was 57·3 months (95% CI 44·2-73·3) for the lenalidomide group and 28·9 months (23·0-36·3) for the placebo group (hazard ratio 0·57, 95% CI 0·46-0·71; p<0·0001). The most common grade 3-4 adverse events were neutropenia (116 50% patients in the lenalidomide group and 41 18% patients in the placebo group) and thrombocytopenia (34 15% patients in the lenalidomide group and 12 5% patients in the placebo group). 18 (8%) haematological and 14 (6%) solid tumour second primary malignancies were diagnosed after randomisation and before disease progression in the lenalidomide group, compared with three (1%) haematological and nine (4%) solid tumour second primary malignancies in the placebo group. Three haematological and five solid tumour second primary malignancies in the placebo group were in the crossover subgroup.
Despite an increase in haematological adverse events and second primary malignancies, lenalidomide maintenance therapy after ASCT significantly improved time to progression and could be considered a standard of care.
The National Cancer Institute.
PDF
